医学
舒尼替尼
肾细胞癌
内科学
舒尼替尼
肿瘤科
酪氨酸激酶抑制剂
索拉非尼
胃肠病学
泌尿科
癌症研究
作者
J. Ayllón,Benoît Beuselinck,Alexandre Morel,Eduardo Barrascout,Jacques Médioni,Florian Scotté,Stéphane Oudard
标识
DOI:10.3109/07357907.2011.568560
摘要
Receptor tyrosine kinase (RTK) inhibitors have revolutionized the treatment of metastatic renal cell carcinoma (mRCC) and significantly extended survival in these patients. Sunitinib is an oral multitargeted inhibitor of vascular endothelial growth factor receptors (VEGFRs-1, -2, and -3), platelet-derived growth factor receptors (PDGFRs-α and -β), stem-cell factor receptor (KIT), FMS-like tyrosine kinase 3 (FLT3), colony-stimulating factor 1 receptor (CSF-1R), and glial cell line-derived neurotrophic factor receptor (REarranged during Transfection; RET). Sunitinib is approved multinationally for the treatment of advanced RCC, and is considered the reference standard of care for first-line treatment. In clinical trials, sunitinib has been associated with a consistent, distinct profile of adverse events. Here we describe three cases that show that it is possible to manage adverse events occurring during sunitinib therapy, and thus allow patients with mRCC to receive an effective dose of sunitinib in order to achieve long-term disease control. These cases also show that surgical resection, performed whenever possible, can help to improve control of metastatic disease and so avoid the unnecessary toxicity and high costs of prolonged antiangiogenic therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI